Abstract: Small cell lung cancer (SCLC) accounts for about 13% of lung cancer. SCLC exhibits an early metastatic potential and sensitivi-ty to first- line cytotoxic chemotherapy compared with non- small cell lung cancer. Current treatments include surgery, radiotherapy, and chemotherapy. Platinum plus etoposide is viewed as the standard first-line chemotherapy. However, recurrence rate of cancer af -ter platinum plus etoposide chemotherapy is high. Topotecan monotherapy is the standard second- line chemotherapy. Meanwhile, novel targeted immunotherapy showed poor effects. Hence, new breakthroughs in the treatment of SCLC are urgently needed.